ArticleAging and disease2015
Clinical Characteristics for the Relationship between Type-2 Diabetes Mellitus and Cognitive Impairment: A Cross-Sectional Study.
Article in Aging and disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 40 citations in OpenAlex.
- The effect of physical activity interventions on cognition function in patients with diabetes: A systematic review and meta-analysis.Diabetes/metabolism research and reviews · 2021Pooled it
- Metformin therapy and cognitive dysfunction in patients with type 2 diabetes: A meta-analysis and systematic review.Medicine · 2020 · on this mapPooled it
- Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis.Journal of Alzheimer's disease : JAD · 2018 · on this mapPooled it
- Metformin provides superior neuroprotective potential compared to semaglutide in preventing diabetes-associated Alzheimer's disease via dual actions.Communications medicine · 2026Article
- Exploring epidemiological risk factors for cerebral amyloid angiopathy: Considerations for monoclonal antibody therapy in people with Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Polyoxidovanadates a new therapeutic alternative for neurodegenerative and aging diseases.Neural regeneration research · 2024Review
- Neurocognitive impairment and its associated factors among patients with diabetes mellitus who have follow up at referral hospital in Northwest, Ethiopia.Frontiers in endocrinology · 2024Article
- Metformin, age-related cognitive decline, and brain pathology.Neurobiology of aging · 2024Article
- Structural and functional connectivity alteration patterns of the cingulate gyrus in Type 2 diabetes.Annals of clinical and translational neurology · 2023Article
- Exploring the Pharmacological Potential of Metformin for Neurodegenerative Diseases.Frontiers in aging neuroscience · 2022Review
- Altered functional hubs and connectivity in type 2 diabetes mellitus with and without mild cognitive impairment.Frontiers in neurology · 2022Article
- Impaired fasting glucose, oxidative distress, and cognitive impairment. Is this the starting point on DBT cognitive decline?Frontiers in aging neuroscience · 2022Review
- Effects of physical activity on cognitive function among patients with diabetes in China: a nationally longitudinal study.BMC public health · 2021Article
- Association between plasma adipsin level and mild cognitive impairment in Chinese patients with type 2 diabetes: a cross-sectional study.BMC endocrine disorders · 2019Article
- Identification of inflammatory and vascular markers associated with mild cognitive impairment.Aging · 2019Article
- Type 1 diabetes-associated cognitive impairment and diabetic peripheral neuropathy in Chinese adults: results from a prospective cross-sectional study.BMC endocrine disorders · 2019Article
- Biomarkers for cognitive decline in patients with diabetes mellitus: evidence from clinical studies.Oncotarget · 2018Article
- Decision-making in primary onset middle-age type 2 diabetes mellitus: a BOLD-fMRI study.Scientific reports · 2017Article
- Sleep and Cognitive Abnormalities in Acute Minor Thalamic Infarction.Neuroscience bulletin · 2016Article
- Differential metformin dose-dependent effects on cognition in rats: role of Akt.Psychopharmacology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We explored the potential differences in cognitive status, lipid and glucose metabolism, ApoEε4 alleles and imaging between diabetic and non-diabetic subjects. 83 subjects with normal cognitive function and 114 mild cognitive impaired patients were divided into four groups by history of diabetes. General demographics was collected from all participants followed by MRI scan, biochemical examinations and a series of neuropsychological tests. Student's t test, multiple regressions and one-way ANOVA were applied to investigate the differences between groups. Comparing diabetic patients with non-diabetic subjects in the mild cognitive impaired group, we found several decreased items in recall of three words in MMSE (p=0.020), AVLT and SCWT (p<0.050). The multiple linear regression revealed that two-hour glucose level (B= -0.255, p<0.001) and fasting C-peptide (B= -0.466, p=0.001) had negative effects on the score of MMSE. In addition, diabetic patients treated with insulin and other diabetes medication performed better in part of the AVLT (p<0.050) compared to patients with insulin treatment or oral antidiabetic medication only. Patients with metformin medication had a better memory outcome compared to patients with sulphonylurea medication in the AVLT long delay free recall (p =0.010). These findings show that patients of mild cognitive impairment with diabetes mellitus have a worse outcome in attention, information processing speed and memory compared to non-diabetic patients. Higher two-hour glucose level and C-peptide level may be risk factors for severe cognitive impairment in type-2 diabetes mellitus patients. The results of this study also suggest that medication may have effects on cognitive function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.